Liu, A. J., Moghadam, A. A., Alam, M. S., Lutz, M. W., Navarra, A., Luo, S., … Murali Doraiswamy, P. (2026). Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. Neurology Open Access, 2(3). https://doi.org/10.1212/wn9.0000000000000121

Liu, Andy J., Alexander A. Moghadam, Mohammad Samsul Alam, Michael W. Lutz, Amber Navarra, Sheng Luo, Laura A. Wang, et al. “Clinical Practice Outcomes With Lecanemab for Alzheimer Disease.” Neurology Open Access 2, no. 3 (September 2026). https://doi.org/10.1212/wn9.0000000000000121.

Liu AJ, Moghadam AA, Alam MS, Lutz MW, Navarra A, Luo S, et al. Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. Neurology Open Access. 2026 Sep;2(3).

Liu, Andy J., et al. “Clinical Practice Outcomes With Lecanemab for Alzheimer Disease.” Neurology Open Access, vol. 2, no. 3, Ovid Technologies (Wolters Kluwer Health), Sept. 2026. Crossref, doi:10.1212/wn9.0000000000000121.

Liu AJ, Moghadam AA, Alam MS, Lutz MW, Navarra A, Luo S, Wang LA, Petrella JR, Whitson H, O’Brien RJ, Johnson KG, Parker D, Beam C, Sanfilippo M, Al-Sahlani H, Cobb S, Liu MY, Murali Doraiswamy P. Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. Neurology Open Access. Ovid Technologies (Wolters Kluwer Health); 2026 Sep;2(3).